Is Ketamine Therapy Addictive? Understanding the Real Risks

Ketamine's addictive potential is real, but the risk from properly supervised ketamine therapy is considered low. Ketamine is a dissociative anesthetic that the Drug Enforcement Administration classifies as a Schedule III controlled substance, a category for drugs with recognized medical uses alongside a documented potential for misuse. Asking whether ketamine therapy is addictive is a responsible question, not an alarmist one, and the honest answer depends heavily on how and where the drug is used.

Clinical ketamine therapy for depression, anxiety, PTSD, or chronic pain differs from recreational ketamine use in dose, frequency, supervision, and intent. Studies of patients receiving ketamine or esketamine (Spravato) in medical settings have generally found low rates of compulsive use, cravings, or inability to stop treatment. Most of the addiction data that worries people comes from studies of unsupervised, high-dose recreational use, a very different pattern of exposure than what happens in a clinic.

Addiction describes compulsive substance use that continues despite harmful consequences, along with a loss of control over how much or how often someone uses a drug. It typically involves two related but distinct features: tolerance, needing a larger dose over time to get the same effect, and physical dependence, withdrawal symptoms when the substance is stopped.

Ketamine can produce pleasurable, dissociative effects that some people want to repeat, and chronic recreational users can develop psychological dependence on those effects. But whether a drug becomes addictive depends heavily on dose, frequency, and context of use, not on the pharmacology of the drug alone.

Most of what researchers know about ketamine addiction comes from studies of people who use it recreationally, often at high doses, several times a week, without medical oversight, and frequently alongside other substances. Clinical ketamine therapy is structured to avoid that pattern in several concrete ways:

• Controlled, sub-anesthetic dosing set by your provider based on your weight, diagnosis, and response
• Limited, spaced sessions rather than open-ended access to the medication
• Direct medical supervision during every session, so a clinician monitors your physical and psychological response in real time
• Therapeutic intent tied to a specific condition and measurable treatment goals, rather than use for intoxication
• No take-home supply for IV infusions or Spravato; both are administered only in a licensed clinical setting

Clinical trials and observational studies of ketamine for treatment-resistant depression have generally reported low rates of addiction-related problems among patients receiving supervised treatment. Patients who complete a treatment series typically say their desire to continue comes from relief of depression, anxiety, or pain, not from craving the drug experience itself.

According to MedlinePlus, a service of the U.S. National Library of Medicine, ketamine injection carries a risk of misuse and dependence, which is why it is dispensed and administered only under close medical supervision. The Drug Enforcement Administration classifies ketamine as a Schedule III controlled substance, a category reserved for drugs with accepted medical use and a moderate potential for physical dependence relative to Schedule I or II substances.

The research base is still relatively young. Most published studies track patients over weeks or months rather than years of ongoing maintenance therapy, so long-term data on extended maintenance protocols remains limited. That is a reasonable point of ongoing vigilance for patients and providers, not a reason to dismiss the existing evidence.

The overall addiction risk from clinical ketamine is low, but it is not the same for everyone. A few factors can raise your individual risk:

• A history of substance use disorder, particularly involving ketamine, other dissociatives, or drugs with similar effects. This does not automatically rule out treatment, but it calls for closer screening and monitoring.
• Unsupervised access to medication. At-home sublingual ketamine programs carry a somewhat higher risk than in-clinic IV or Spravato treatment because you hold the medication yourself between doses. See our guide on at-home sublingual ketamine for anxiety for how reputable programs manage that risk.
• Using ketamine outside your prescribed protocol, such as taking more than prescribed or using it for reasons unrelated to your treatment plan.

Provider selection matters here. Our coverage of the federal investigation into online ketamine sellers looks at what can go wrong when at-home ketamine is dispensed with minimal screening.

Some patients need ongoing ketamine maintenance sessions to sustain improvements in mood or pain control. That is therapeutic dependence, similar to needing insulin for diabetes or a daily antidepressant for major depression: the brain benefits from regular treatment, and symptoms tend to return when treatment stops. See what happens when ketamine stops working for a closer look at that pattern, and our guide to NMDA antagonist discontinuation rates for how that compares across similar treatments.

Dependence like this is different from addiction. Addiction involves compulsive use, loss of control, and continued use despite harm. Needing ketamine to maintain your mental health gains is not the same as being addicted to it, and a thoughtful maintenance plan built around your actual clinical response is a normal part of treatment, not a red flag.

Tolerance, needing a higher dose for the same effect, is possible with repeated ketamine use. It can develop quickly in recreational users taking frequent, high doses. In clinical settings, with controlled dosing and spaced sessions, meaningful tolerance is less common but can still happen. If your sessions start to feel less effective, or the effects feel diminished at your usual dose, tell your provider. They can evaluate whether tolerance is developing and adjust your protocol, which might mean changing the dose, the route of administration, or the interval between sessions.

The single most effective way to reduce your addiction risk is complete honesty with your treatment team. That means being upfront about your substance use history, including alcohol and prescription medications; how the ketamine experience makes you feel, both therapeutically and otherwise; any urges to use ketamine outside your treatment plan; and any changes in your behavior or thinking related to the medication.

Your provider cannot help you manage a risk they do not know about. If you would rather prepare specific questions before a visit, our list of questions to ask a ketamine provider covers what to raise about screening, monitoring, and continuity of care.

Ketamine therapy, delivered under proper medical supervision with real screening and monitoring, carries a low risk of addiction. That risk profile is meaningfully different from the addiction potential tied to unsupervised recreational use. Controlled dosing, limited frequency, medical oversight, and ongoing assessment exist specifically to keep that risk low.

If you are weighing ketamine therapy, our guide to ketamine therapy safety covers the broader risk picture beyond addiction, and our guide to getting started walks through what a first course of treatment typically looks like. If you have concerns about addiction risk, raise them with your provider before you start.